Please provide your email address to receive an email when new articles are posted on . Retina specialists need to know when to consult with neuro-ophthalmology. The key to understanding when to ...

Andrew G. Lee, MD, and Drew Carey, MD, highlight how chronic lymphocytic leukemia can mimic Graves’ orbitopathy, underscoring ...

Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical ...

ORLANDO — In this Healio Video Perspective from Telling It Like It Is, Andrew G. Lee, MD, explains why a team approach is needed for neuro-ophthalmic conditions. According to Lee, conditions involving ...

Privosegtor (also known as OCS-05) is a “first-in-class peptoid small molecule” for neuroprotective therapy for acute optic ...

BUFFALO, N.Y. — A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a direct causal link with the drugs has not been established.

Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic ...

Premiere Eye Referral Center and Optical (PERC) has unveiled its groundbreaking services in ophthalmic care - LASIK & ...

Privosegtor is Oculis ' second ophthalmic drug to start a pivotal trials programme after OCS-01, a topical anti-TNF drug in ...